Alexandru Apostu

Dr. Alexandru Apostu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Medicina
Verified
Journal Article
Open access
PDF file
GCGabriel Veniamin Cozma
Gabriel Veniamin Cozma
AAAlexandru Apostu
Alexandru Apostu
IMIoana Macasoi
Ioana Macasoi
CRISTINA ADRIANA DEHELEANCRISTINA ADRIANA DEHELEAN
CRISTINA ADRIANA DEHELEAN
OCOctavian Marius Cretu
Octavian Marius Cretu
AMAniko Manea
Aniko Manea
Background and Objectives: Metformin is currently the leading drug of choice for treating type 2 diabetes mellitus, being one of the most widely used drugs worldwide. The beneficial effects of Metformin, however, extend far beyond the reduction of blood glucose. Therefore, this study aimed to evaluate Metformin’s effects both in vitro and in ovo. Materials and Methods: Metformin has been tested in five different concentrations in human hepatocytes —HepaRG, in terms of cell viability, morphology, structure and number of nuclei and mitochondria, as well as the effect on cell migration. Through the application of HET-CAM, the biocompatibility and potential anti-irritant, as well as protective effects on the vascular plexus were also assessed. Results: According to the results obtained, Metformin increases cell viability without causing morphological changes to cells, mitochondria, or nuclei. Metformin displayed an anti-irritant activity rather than causing irritation at the level of the vascular plexus. Conclusions: In conclusion, Metformin enhances cell viability and proliferation and, has a protective effect on the vascular plexus. Nonetheless, more studies are required to clarify the mechanism of hepatoprotective effect of metformin.